TL;DR
This study demonstrates that Indocyanine Green (ICG) fluorescence imaging, already a staple in treating common pediatric liver cancers, is a highly effective "GPS" for resecting rare pediatric liver tumors. By correlating specific fluorescence patterns (total, partial, or rim) with tumor histopathology, surgeons can better differentiate tumor types intraoperatively and achieve higher rates of complete, tissue-sparing resections.
What Problem Does This Paper Address?
Pediatric liver tumors are rare, accounting for only 1–4% of all childhood cancers. While hepatoblastoma (HB) makes up the vast majority of these cases, surgeons occasionally encounter much rarer subtypes like undifferentiated embryonal sarcoma (UESL) or hepatic mesenchymal hamartoma (HMH).
The clinical challenge is two-fold:
- Identification: Distinguishing between benign and malignant rare tumors during surgery is difficult.
- Precision: Surgeons aim for "R0 resection" (removing the entire tumor with no cancer cells at the margin) while preserving as much healthy liver tissue as possible to improve long-term outcomes.
While ICG-NIR (Near-Infrared) imaging is well-established for common hepatoblastomas, its utility and the specific "fluorescence signatures" of these rarer tumors have remained largely undocumented.
Methods
The researchers conducted a retrospective study of 23 children with rare (non-hepatoblastoma) liver tumors at Beijing Children’s Hospital.
- The Agent: Indocyanine Green (ICG), a fluorescent dye, was administered intravenously 0–3 days before surgery.
- The Tech: Surgeons used a variety of NIR imaging systems, including open-field cameras, laparoscopic setups, and the da Vinci® robotic system.
- The Classification: They categorized the resulting fluorescence into four patterns:
- Total: The entire tumor glows brightly.
- Partial: Patchy or focal fluorescence.
- Rim: The tumor is dark, but surrounded by a glowing ring.
- Negative: No fluorescence at all.
- The Correlation: These patterns were then compared against the "gold standard" of post-operative histopathology to see if the glow could predict the tumor type.
Datasets
As a clinical study, the "dataset" consists of a patient cohort rather than a digital benchmark. The study reviewed 130 children with liver tumors, narrowing down to 23 patients with rare, non-HB tumors where ICG-NIR was utilized. This cohort included benign (52.2%), malignant (34.8%), and metastatic (13.0%) lesions.
Key Insights and Ideas
- The Mechanism of the Glow: ICG is normally taken up by hepatocytes (liver cells) and excreted into bile. In tumors, this process breaks down.
- Epithelial tumors (like FNH) take up ICG but can't excrete it, leading to Total fluorescence.
- Mesenchymal/Malignant tumors (like UESL) don't take up ICG, but they compress the surrounding healthy liver tissue, causing ICG to "back up" in the periphery, creating a Rim pattern.
- The "HMH Exception": Hepatic mesenchymal hamartomas (HMH) are mesenchymal in origin, which usually suggests a rim pattern. However, they showed Total fluorescence. Histopathology revealed that these tumors have healthy hepatocytes and bile ducts "trapped" inside the tumor structure, which catch and hold the ICG.
- Chemotherapy's Impact: Metastatic neuroblastoma (NBLM) showed Negative fluorescence. The authors suggest that because these tumors are highly sensitive to chemotherapy, they shrink significantly, reducing the "mass effect" that usually causes ICG retention in surrounding tissues.
Key Results
- Surgical Success: 91.3% (21/23) of the children achieved a complete (R0) resection.
- Safety: Zero adverse reactions to ICG were reported, confirming its safety profile in pediatric populations.
- Pattern Accuracy:
- 81.8% of tumors of hepatocytic origin showed a Total pattern.
- 66.7% of non-hepatocytic malignancies exhibited a Rim pattern.
- Recovery: Most patients experienced only minor (Grade II) complications, and 87% remained disease-free at the median 7.5-month follow-up.
Limitations and Future Work
- Depth Perception: NIR light only penetrates about 1 cm into the tissue. Deeply seated tumors may appear "partial" or "negative" simply because the light cannot reach them.
- Sample Size: While 23 cases is significant for rare tumors, it is still a small cohort. The authors call for multicenter prospective trials to validate these patterns across larger populations.
- Equipment Sensitivity: The study noted that different imaging systems (e.g., robotic vs. open) have varying levels of sensitivity, which can affect the perceived fluorescence pattern.
- Molecular Level: The study provides a clinical overview; the authors note that more research is needed at the cellular and molecular levels to fully understand ICG transporter expression in these rare subtypes.
Summary updated